8 years of historical data (2018–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
C4 Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $262M | $158M | $250M | $280M | $288M | $1.5B | $1.4B | — | — |
| Enterprise Value | $247M | $144M | $260M | $225M | $346M | $1.4B | $1.3B | — | — |
| P/E Ratio → | -2.13 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 7.02 | 13.51 | 9.27 | 32.38 | 42.98 | — | — |
| P/B Ratio | 0.87 | 0.62 | 1.16 | 1.14 | 1.00 | 3.81 | 5.08 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 7.31 | 10.83 | 11.12 | 31.65 | 38.19 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Operating margins have expanded from -669.8% to -336.1% over the past 3 years, signaling improving operational efficiency. A negative ROE of -44.4% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | 62.7% | 100.0% | 100.0% | -136.3% | 100.0% | -47.7% |
| Operating Margin | — | — | -336.1% | -669.8% | -416.6% | -179.4% | -182.1% | -165.8% | -84.6% |
| Net Profit Margin | — | — | -296.0% | -638.3% | -412.2% | -183.2% | -199.8% | -159.5% | -81.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -44.4% | -44.4% | -45.6% | -49.5% | -37.8% | -25.0% | -78.6% | — | — |
| ROA | -29.6% | -29.6% | -29.0% | -32.8% | -27.3% | -18.5% | -25.6% | -25.8% | -10.7% |
| ROIC | -36.9% | -36.9% | -43.1% | -38.8% | -27.6% | -25.8% | -37.2% | — | — |
| ROCE | -36.6% | -36.6% | -37.5% | -38.6% | -30.8% | -20.2% | -27.4% | -34.2% | -13.4% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $75M exceeds total debt of $60M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.23 | 0.23 | 0.30 | 0.29 | 0.30 | 0.11 | 0.08 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.06 | 0.05 | -0.23 | 0.20 | -0.09 | -0.57 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | -1.42 | — |
| Interest Coverage | — | — | — | -101.26 | -58.45 | -38.29 | -49.19 | — | — |
Net cash position: cash ($75M) exceeds total debt ($60M)
Short-term solvency ratios and asset-utilisation metrics
C4 Therapeutics, Inc.'s current ratio of 7.81x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 6.34x to 7.81x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.81 | 7.81 | 5.71 | 6.34 | 6.46 | 6.36 | 8.69 | 2.88 | 5.16 |
| Quick Ratio | 7.81 | 7.81 | 5.71 | 6.34 | 7.82 | 6.36 | 8.69 | 2.88 | 5.16 |
| Cash Ratio | 7.52 | 7.52 | 5.42 | 5.93 | 6.20 | 6.04 | 8.48 | 2.69 | 1.52 |
| Asset Turnover | — | — | 0.10 | 0.06 | 0.07 | 0.09 | 0.08 | 0.18 | 0.13 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 31.82 | 207.49 | 17.29 | 45.57 | 49.30 | 78.92 | 1629.31 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
C4 Therapeutics, Inc. returns 0.1% to shareholders annually primarily through share buybacks.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.1% | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.1% | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $83M | $69M | $50M | $49M | $46M | $43M | $43M | $42M |
Compare CCCC with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| CCCCYou | $262M | -2.1 | — | — | — | — | -44.4% | -36.9% | — |
| REGN | $108B | 18.8 | 21.6 | 26.4 | 86.3% | 25.7% | 14.9% | 12.4% | 0.6 |
| CNTA | $4B | -13.0 | — | — | — | — | -73.9% | -91.8% | — |
| IMNM | $2B | -4.4 | — | — | 100.0% | -3382.4% | -194.6% | -700.3% | — |
| CLDX | $2B | -7.7 | — | — | 100.0% | -19160.0% | -40.6% | -35.2% | — |
| RXRX | $2B | -2.5 | — | — | 5.0% | -867.9% | -59.5% | -95.8% | — |
| NRIX | $2B | -5.2 | — | — | 77.5% | -340.2% | -49.6% | -54.0% | — |
| ROIV | $1B | -120.6 | — | — | 96.9% | -3453.3% | -3.0% | -50.4% | — |
| ABCL | $1B | -7.4 | — | — | — | -289.0% | -14.5% | -16.8% | — |
| ARVN | $975M | -10.4 | — | — | -151.8% | -45.1% | -16.2% | -23.1% | — |
| XNCR | $918M | -10.3 | — | — | — | — | -9.5% | — | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 8 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how CCCC stacks up against sector leader Regeneron Pharmaceuticals, Inc..
Start ComparisonC4 Therapeutics, Inc.'s current P/E ratio is -2.1x. This places it at the 50th percentile of its historical range.
C4 Therapeutics, Inc.'s return on equity (ROE) is -44.4%. The historical average is -46.8%.
Based on historical data, C4 Therapeutics, Inc. is trading at a P/E of -2.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.